Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Mebeverine→

Mebeverine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
3625-06-7
Molecular formula
C25H35NO5
Molecular weight
429.5 g/mol
Drug class
Musculotropic gastrointestinal antispasmodic
Mechanism of action
Acts directly on gastrointestinal smooth muscle without materially affecting normal gut motility. The exact mechanism is not fully known; proposed contributing actions include altered ion-channel permeability, noradrenaline reuptake inhibition, local anaesthetic activity and weak antimuscarinic/phosphodiesterase effects.
Indications / reported uses
  • Symptomatic treatment of irritable bowel syndrome
  • Other functional bowel conditions associated with colicky abdominal pain, cramps, spastic constipation, diarrhoea and flatulence, according to product information

Sources: UK SmPC — Mebeverine 135 mg tablets (updated 9 Apr 2026) · UK SmPC — Mebeverine MR 200 mg capsules · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Musculotropic gastrointestinal antispasmodic

Mechanism of action

Acts directly on gastrointestinal smooth muscle without materially affecting normal gut motility. The exact mechanism is not fully known; proposed contributing actions include altered ion-channel permeability, noradrenaline reuptake inhibition, local anaesthetic activity and weak antimuscarinic/phosphodiesterase effects.

General use cases

  • Symptomatic treatment of irritable bowel syndrome
  • Other functional bowel conditions associated with colicky abdominal pain, cramps, spastic constipation, diarrhoea and flatulence, according to product information

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Mebeverine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mebeverine Permitted Daily Exposure (PDE) report (the Mebeverine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mebeverine Occupational Exposure Limit (OEL) report (the Mebeverine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.